Bioline Rx Stock Number Of Shares Shorted
| BLRX Stock | ILS 8.10 0.10 1.25% |
BioLine RX fundamentals help investors to digest information that contributes to BioLine RX's financial success or failures. It also enables traders to predict the movement of BioLine Stock. The fundamental analysis module provides a way to measure BioLine RX's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to BioLine RX stock.
BioLine |
BioLine RX Company Number Of Shares Shorted Analysis
BioLine RX's Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, BioLine RX has 0.0 of outstending shares currently sold short by investors. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The number of shares shorted for all Israel stocks is 100.0% higher than that of the company.
Did you try this?
Run Price Ceiling Movement Now
Price Ceiling MovementCalculate and plot Price Ceiling Movement for different equity instruments |
| All Next | Launch Module |
BioLine Fundamentals
| Return On Equity | -0.37 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | (13.02 M) | |||
| Shares Outstanding | 922.87 M | |||
| Shares Owned By Insiders | 0.25 % | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.77 X | |||
| EBITDA | (25.37 M) | |||
| Net Income | (27.05 M) | |||
| Cash And Equivalents | 40.61 M | |||
| Cash Per Share | 0.28 X | |||
| Total Debt | 10.69 M | |||
| Debt To Equity | 23.20 % | |||
| Current Ratio | 5.12 X | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (23.57 M) | |||
| Earnings Per Share | (0.03) X | |||
| Target Price | 3.0 | |||
| Number Of Employees | 38 | |||
| Beta | 1.27 | |||
| Market Capitalization | 135.72 M | |||
| Total Asset | 81.39 M | |||
| Retained Earnings | (163 M) | |||
| Working Capital | 43 M | |||
| Current Asset | 46 M | |||
| Current Liabilities | 3 M | |||
| Z Score | 4.4 | |||
| Net Asset | 81.39 M |
About BioLine RX Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze BioLine RX's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLine RX using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLine RX based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in BioLine Stock
BioLine RX financial ratios help investors to determine whether BioLine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BioLine with respect to the benefits of owning BioLine RX security.